Natco Pharma Q1 net, revenue slump on lower cancer drug sales
Natco Pharma reported a 57% year-on-year decline in net profit for Q1, falling to ₹206.5 crore, due to lower sales of the generic cancer drug Lenalidomide. Total revenue also dropped nearly 43% to ₹794.4 crore, reflecting the impact of reduced earnings from this key product. The company's shares fell over 5% following the announcement.